• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Mnemosyne Pharmaceuticals

edit

Mnemosyne Pharmaceuticals, Inc. is developing an innovative drug discovery platform that will address medical needs in several segments of the mental health market.

Mnemosyne was founded in 2010 with seed funding from Slater Technology Fund and private investors. Recently, Mnemosyne closed on a Series A round totaling $5.4M. Mnemosyne is using these funds to develop a new class of small molecule drugs that modulate the activity of different subtypes of the NMDA receptor.

Recent Milestones

edit

• 
  Mnemosyne Pharmaceuticals received $5.4M in Series A funding. (2/16/12)
  Posted 2/16/12 at 6:17pm via masshightech.com
• 
  Mnemosyne Pharmaceuticals added Kollol Pal as CEO.
  Posted 2/16/12 at 6:17pm
• 
  Mnemosyne Pharmaceuticals added Frank S. Menniti as Chief Scientific Officer.
  Posted 2/16/12 at 6:17pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 2/17/12

Sources

1. Mnemosyne Pharmaceuticals lands $5.4M in Series A round (masshightech.com) [edit]